Pooled analyses of MIF rs755622 in patients with SSc, SSc phenotypic and serological subgroups, and unaffected controls.
| Subgroup | MAF, % | p* | OR (CI 95%)** |
|---|---|---|---|
| Controls, n = 16,591 | 15.93 | ||
| SSc, n = 4392 | 16.32 | 0.093 | 1.06 (0.99–1.14) |
| LcSSc, n = 3058 | 15.89 | 0.331 | 1.04 (0.96–1.12) |
| DcSSc, n = 1334 | 17.25 | 0.032 | 1.13 (1.01–1.26) |
| ACA+, n = 1814 | 15.93 | 0.301 | 1.05 (0.96–1.17) |
| Anti-topo I+, n = 1079 | 16.68 | 0.071 | 1.12 (0.99–1.27) |
| PF+, n = 1274 | 16.25 | 0.257 | 1.07 (0.95–1.19) |
| PAH+, n = 230 | 19.13 | 0.0219 | 1.32 (1.04–1.67) |
Six white European cohorts are included: Spain, Germany, the Netherlands, Italy, the United Kingdom, and Norway.
↵* Unaffected controls are used as reference for the global set of the disease and for each phenotype comparison.
↵** OR for the minor allele. SSc: systemic sclerosis; MAF: minor allele frequency; lcSSc: limited cutaneous SSc; dcSSc: diffuse cutaneous SSc; ACA: anticentromere antibodies; anti-topo I: antitopoisomerase antibodies; PF: pulmonary fibrosis; PAH: pulmonary arterial hypertension.